BR9809306A - Inibidores de protease - Google Patents

Inibidores de protease

Info

Publication number
BR9809306A
BR9809306A BR9809306-1A BR9809306A BR9809306A BR 9809306 A BR9809306 A BR 9809306A BR 9809306 A BR9809306 A BR 9809306A BR 9809306 A BR9809306 A BR 9809306A
Authority
BR
Brazil
Prior art keywords
protease inhibitors
keto
hydroxy
cyclohetero
tetrahydrothiopyran
Prior art date
Application number
BR9809306-1A
Other languages
English (en)
Inventor
Andrew D Gribble
Ashley Edward Fenwick
Robert W Marquis Jr
Daniel F Veber
Jason Witherington
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp
Publication of BR9809306A publication Critical patent/BR9809306A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"INIBIDORES DE PROTEASE" A presente invenção refere-se a compostos de leucina 3-hidróxi- e 3-ceto-ciclohetero-substituídos que são inibidores de protease cisteína, particularmente catepsina K, e são úteis no tratamento de doenças que a inibição de perda óssea é um fator. A porção 3-hidróxi ou 3-ceto- é ligada ao anel tetraidrotiofeno, tetraidrotiopirano ou tetraidropirano.
BR9809306-1A 1997-05-06 1998-05-06 Inibidores de protease BR9809306A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4575897P 1997-05-06 1997-05-06
PCT/US1998/003200 WO1998050533A1 (en) 1997-05-06 1998-05-06 Protease inhibitors

Publications (1)

Publication Number Publication Date
BR9809306A true BR9809306A (pt) 2000-07-04

Family

ID=21939723

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809306-1A BR9809306A (pt) 1997-05-06 1998-05-06 Inibidores de protease

Country Status (19)

Country Link
EP (1) EP1003846A4 (pt)
JP (1) JP2001525804A (pt)
KR (1) KR20010012256A (pt)
CN (1) CN1255161A (pt)
AR (1) AR013079A1 (pt)
AU (1) AU7562598A (pt)
BR (1) BR9809306A (pt)
CA (1) CA2288868A1 (pt)
CO (1) CO4950618A1 (pt)
HU (1) HUP0002247A3 (pt)
IL (1) IL132088A0 (pt)
NO (1) NO995434D0 (pt)
NZ (1) NZ337889A (pt)
PE (1) PE71599A1 (pt)
PL (1) PL336856A1 (pt)
TR (1) TR199902766T2 (pt)
UY (1) UY25143A1 (pt)
WO (1) WO1998050533A1 (pt)
ZA (1) ZA983762B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5150165A1 (es) * 1998-11-13 2002-04-29 Smithkline Beecham Plc Inhibidores de proteasa: tipo catepsina k
DZ3083A1 (fr) * 1999-02-19 2004-06-02 Smithkline Beecham Corp Composés nouveaux inhibiteurs de protéases, procédé pour leur préparation et compositions pharmaceutiques les conentant.
GB9911417D0 (en) * 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
WO2001034599A1 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
US20040024000A1 (en) * 2000-10-19 2004-02-05 Rajeshwar Singh Dihydropyrimidine derivatives as cysteine protease inhibitors
JP2004513942A (ja) * 2000-11-17 2004-05-13 メディヴァー　ユーケイ　リミテッド システインプロテアーゼインヒビター
JP2004520439A (ja) * 2000-11-17 2004-07-08 メディヴィル・アクチボラグ システインプロテアーゼインヒビター
JP2004522738A (ja) * 2001-01-17 2004-07-29 アミュラ テラピューティクス リミテッド クルジパインおよび他のシステインプロテアーゼの阻害剤としての環状２−カルボニルアミノケトン
US7132449B2 (en) 2001-01-17 2006-11-07 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
AU2002219397B2 (en) * 2001-01-17 2008-02-14 Grünenthal GmbH Inhibitors of cruzipain and other cysteine proteases
NZ526912A (en) * 2001-01-17 2005-02-25 Amura Therapeutics Ltd Inhibitors of cruzipain and other cysteine proteases
WO2003037892A1 (en) * 2001-10-29 2003-05-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
NZ537853A (en) * 2002-07-16 2007-02-23 Amura Therapeutics Ltd Inhibitors of cathepsin K and related cysteine protesases of the CA clan
KR100962972B1 (ko) 2002-07-26 2010-06-09 주식회사유한양행 1-페닐피페리딘-3-온 유도체 및 그의 제조방법
BRPI0413324A (pt) 2003-08-06 2006-10-10 Senomyx Inc receptores de paladar hetero-oligoméricos t1r, linhas de células que expressam os ditos receptores, e compostos de paladar
AU2016206281B2 (en) * 2003-08-06 2017-11-30 Senomyx, Inc. Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
DE602005019971D1 (de) * 2004-01-08 2010-04-29 Medivir Ab Inhibitoren von cysteinprotease
CA2619706A1 (en) * 2005-08-17 2007-02-22 Schering Corporation Novel high affinity quinoline-based kinase ligands
GB0614042D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
MX2009012847A (es) * 2007-06-13 2009-12-08 Bristol Myers Squibb Co Analogos dipeptidicos como inhibidores de factores de coagulacion.
US7893067B2 (en) 2007-06-27 2011-02-22 Medivir Ab Cysteine protease inhibitors
EP2240491B1 (en) 2008-01-09 2015-07-15 Amura Therapeutics Limited TETRAHYDROFURO(2,3-b)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES
GB0817424D0 (en) * 2008-09-24 2008-10-29 Medivir Ab Protease inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3190431B2 (ja) * 1991-07-01 2001-07-23 三菱化学株式会社 ケトン誘導体
JPH05140063A (ja) * 1991-11-19 1993-06-08 Suntory Ltd ジペプチド誘導体及びそれを有効成分とする骨疾患の予防及び治療剤
CA2111930A1 (en) * 1992-12-25 1994-06-26 Ryoichi Ando Aminoketone derivatives
JP2848232B2 (ja) * 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
JP3599287B2 (ja) * 1993-04-28 2004-12-08 三菱化学株式会社 スルホンアミド誘導体
US5403952A (en) * 1993-10-08 1995-04-04 Merck & Co., Inc. Substituted cyclic derivatives as novel antidegenerative agents
SK88997A3 (en) * 1995-10-30 1998-05-06 Smithkline Beecham Corp Method of inhibiting cathepsin k
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
WO1998004539A1 (fr) * 1996-07-29 1998-02-05 Mitsubishi Chemical Corporation Derives heterocycliques oxygenes

Also Published As

Publication number Publication date
NO995434L (no) 1999-11-05
KR20010012256A (ko) 2001-02-15
TR199902766T2 (xx) 2000-02-21
CA2288868A1 (en) 1998-11-12
EP1003846A1 (en) 2000-05-31
WO1998050533A1 (en) 1998-11-12
NO995434D0 (no) 1999-11-05
PL336856A1 (en) 2000-07-17
UY25143A1 (es) 1998-11-27
CO4950618A1 (es) 2000-09-01
JP2001525804A (ja) 2001-12-11
IL132088A0 (en) 2001-03-19
AR013079A1 (es) 2000-12-13
AU7562598A (en) 1998-11-27
CN1255161A (zh) 2000-05-31
HUP0002247A3 (en) 2003-01-28
PE71599A1 (es) 1999-09-15
HUP0002247A2 (hu) 2001-05-28
EP1003846A4 (en) 2002-11-13
NZ337889A (en) 2001-09-28
ZA983762B (en) 1998-11-06

Similar Documents

Publication Publication Date Title
BR9809306A (pt) Inibidores de protease
MY119155A (en) New peptide derivatives
HUP0303143A2 (hu) A VII-es faktor és a IX-es faktor polipeptidek kombinált alkalmazása
PT1465626E (pt) Composições farmacêuticas (kit) que compreendem compostos di-hidropiridinona e um agente imunorregulador (ou antiinflamatório) e suas utilizações
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
CL2003001743A1 (es) Compuestos derivados de leucinamida, inhibidores de la cisteina proteasa; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y su uso en el tratamiento de la osteoporosis, enfermedad de paget's, peridontal, perdida
WO1995021601A3 (en) Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof
WO2000053758A3 (en) Compositions and methods for the treatment of immune related diseases
MY122696A (en) Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases.
WO2002069901A3 (en) Cathepsin cysteine protease inhibitors
PL343373A1 (en) Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily
MXPA04003796A (es) Tioacetamidas sustituidas.
MXPA02011288A (es) Tioacetamidas substituidas.
HK1025737A1 (en) Treatment of multiple sclerosis through ingestion of copolymer-1
WO2000073452A3 (en) Compositions and methods for the treatment of immune related diseases
BR9815469A (pt) Inibidores de protease
HUP0001014A2 (hu) Gasztrointesztinális lipáz inhibitorok felhasználása
BR0211186A (pt) peptìdeos e uso dos mesmos no escurecimento da pele
MY139368A (en) Novel cyclohexyl sulphones
WO1999014241A3 (en) Compositions and methods for the treatment of immune related diseases
IS1910B (is) Notkun á fankínóni til meðhöndlunar á Alzheimers-sjúkdómi
HUP0202729A2 (hu) Ösztramusztin-foszfátot és aminosavakat tartalmazó, parenteralis felhasználásra szolgáló készítmények
ZA966047B (en) Therapeutic agents.
AR021241A1 (es) Inhibidores de proteasas
WO2004024077A3 (en) Novel composition and methods for the treatment of psoriasis

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]